drugset / Trial / NCT03752723
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
Non-randomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety and tolerability of escalating doses GX-I7 in combination with standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with refractory or relapsed TNBC
Timeline
- Start
- 2019-03-27
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | NT-I7 | Protein / enzyme biologic | — | Intramuscular |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |